Brennan Nora 4
4 · TELA Bio, Inc. · Filed Nov 13, 2019
Insider Transaction Report
Form 4
TELA Bio, Inc.TELA
Brennan Nora
Chief Financial Officer
Transactions
- Conversion
Common Stock
2019-11-13+3,491→ 3,668 total - Conversion
Series B Preferred Stock
2019-11-13−86,200→ 0 total→ Common Stock (3,491 underlying)
Footnotes (3)
- [F1]Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
- [F2]Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.
- [F3]Reflects 177 shares of common stock received by the reporting person as a payment-in-kind dividend on Series B Preferred Stock exempt from reporting under Rule 16a-9(a).